WilmerHale has a notable record in representing growth companies in IPOs and other equity offerings, particularly those in the life sciences and technology sectors. In 2023, it continued to advise issuers in mid-market public offerings and follow-on offerings, especially those by life sciences issuers. Boston partners Stuart Falber and Cynthia Mazareas are noted for life sciences sector offerings with Lisa Firenze and Brian Johnson being key figures in New York. Caroline Dotolo is another ‘go to’ partner in Boston.
Testimonials
Collated independently by Legal 500 research team.
‘The teams at Wilmer work exceptionally well together. I find that no matter who I reach out to, I am provided with consistent, strong advice. I also have been very happy in the past with the staffing of teams - it has always been an efficient mix of levels, and the teams have delivered well.’
‘I find the subject matter expertise of the capital markets partners at Wilmer is exceptional. They are prepared for any situation that may arise and have the expertise to address it when it does. Caroline Dotolo, in particular, has done exceptional work for us in the past and is our "go to" partner for equity offerings and related matters.’
Key clients
- Apellis Pharmaceuticals
- Casella Waste Systems
- Nuvalent, Inc.
- Karyopharm Therapeutics, Inc.
- Inozyme Pharma, Inc.
- Cue Biopharma
- Curis, Inc.
- MKS Instruments
- Kala Pharmaceuticals
Work highlights
- Represented Apellis Pharmaceuticals in its $402.5m follow-on offering.
- Represented Casella Waste Systems in connection with its public offering of 6,052,631 shares of its Class A Common Stock.
- Represented Nuvalent in its $264.5m public offering of common stock.
Practice head
The lawyer(s) leading their teams.
Brian Johnson, Lisa Firenze